- Egypt rights center raided, 2 Mubaraks acquitted
- New Mexico Supreme Court rules same-sex marriage constitutional
- Blame Bush: 5 years later, that’s still the mantra, pollsters find
- Dutch prostitutes demand same retirement benefits as soccer stars
- John McCain to Harry Reid: I’ll ‘kick the crap’ out of you
- Dogs that talk: Researchers seek $10K for ‘No More Woof’ technology
- 1,000 firefighters called to battle stubborn Big Sur wildfire
- Black Friday brouhaha: Millions of Target shoppers hit by credit card theft
- Britain orders airplane to rescue citizens from violent South Sudan
- Mega Millions winner emerges as Georgia mom, in ‘disbelief’
NewsNow: Pfizer to buy King Pharmaceuticals
Question of the Day
NEW YORK (AP) - Pfizer says it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world’s largest drug company.
Pfizer Inc. says it is paying $14.25 a share for King Pharmaceuticals Inc. in Bristol, Tenn. That’s a premium of 40 percent to the stock’s closing price Monday. Some of the products Pfizer gains include the pain drug Avinza and Embeda, a pain treatment designed to be resistant to drug abuse.
King has struggled in recent years as patents on several key drugs have expired and generic drugs have eaten into the company’s profits. Pfizer faces the same problem in the next five years as the patents on nine of its top sellers expire.
THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP’s earlier story is below.
Pfizer is paying $14.25 per share for King. That’s a premium of 40 percent to the stock’s Monday closing price of $10.15. In the deal Pfizer gains products including the pain drug Avinza and EpiPen, a pre-filled injection designed to quickly treat serious allergic reactions.
King has struggled in recent years as patents on several of its key drugs have expired or been thrown out. But the Bristol, Tenn., company is heavily involved in developing pain drugs that are intended to be abuse-resistant. Abuse of pain drugs like oxycodone has become a major concern for health officials and regulators in recent years. The drugs are often crushed or dissolved to defeat their time-release mechanisms, allowing users to get high.
King’s Embeda is one pain treatment that is designed to resist abuse attempts. King plans to file new applications for two similar drugs in the next few months, filing for approval of Remoxy in the fourth quarter of 2010 and Acurox in the first quarter of 2011. Remoxy and Embeda are extended-release drugs, while Acurox releases its painkilling ingredient immediately.
The boards of both companies approved the deal. Pfizer said the purchase will add about 2 cents per share to its net income in 2011 and 2012, and 3 to 4 cents per share in each of the next three years. It does not expect the deal to affect its 2010 results. The company currently expects to earn $2.10 to $2.20 per share on revenue of about $68 billion.
The companies did not say if jobs would be eliminated after the deal closes. King says it has about 2,600 employees. Pfizer had 116,500 workers at the end of 2009, but is cutting thousands of jobs in the wake of the Wyeth deal.
By Andrew P. Napolitano
Fourth Amendment says Obama is not at liberty to collect metadata
- Calling sentence disparities unfair, Obama pardons 8 crack offenders
- Homeland Security helps smuggle illegal immigrant children into the U.S.
- Gov't wasted $30 billion on 'pillownauts,' crystal goblets -- buying human urine!
- Bill Gates: The Secret Santa disguised as a 'friendly fellow' on Reddit
- Armed response, not restrictive gun laws, brought swift end to school shooting
- Obamacare 'pajamas boy' gets roundly mocked
- BOLTON: Nero in the White House
- Duck Dynasty Phil Robertson suspended indefinitely for gay quip
- U.S. Army mulls wiping out memory of Robert E. Lee, 'Stonewall' Jackson
- Outrage over Phil Robertson suspension, 'malignant' political correctness
Independent voices from the The Washington Times Communities
The world impacts us. What happens in our towns, cities, states, country and on this planet makes a difference to us.
Brazen, leading-edge, “call it like it is” columns and reporting from Ohio native, radio host and writer, Sara Marie Brenner.
Crystal Wright is a black conservative woman living in Washington, D.C.
Wall Street news for retail investors who want to know what's going on.
Top 10 handguns in the U.S.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow